Kitty Yale

2.6k citations

21 papers · 1.9k indexed · 3 hit papers · h-index 16

Impact in

Virology top 0.5%
- HIV Research and Treatment
Infectious Diseases top 1%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in ⓘ

Virology 11
- HIV Research and Treatment 11
Infectious Diseases 11
- HIV/AIDS drug development and treatment 11
- HIV/AIDS Research and Interventions 7

Co-authors: Andrew Cheng (11 shared papers)Brian P. Kearney (8 shared papers)Edwin DeJesus (5 shared papers)Lijie Zhong (5 shared papers)Peter Ruane (5 shared papers)Kirsten White (3 shared papers)Javier Szwarcberg (2 shared papers)Tim Rolph (9 shared papers)
Journals: Journal of Hepatology (3 papers)The Lancet (3 papers)PEDIATRICS (2 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (1 paper)Nature Medicine (1 paper)
Partner nations: United States United Kingdom France

In The Last Decade

Kitty Yale

19 papers receiving 1.8k citations

Hit Papers

align trajectories log scale

Efruxifermin in Compensated Liver Cirrhosis Caused by MASH 2025 · 19 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2025 New England Journal of Medicine
2023 The Lancet. Gastroenterology & hepatology
2021 Nature Medicine

Peers

Countries citing papers authored by Kitty Yale

Since Specialization

Citations

This map shows the geographic impact of Kitty Yale's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kitty Yale with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kitty Yale more than expected).

Fields of papers citing papers by Kitty Yale

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kitty Yale. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kitty Yale. The network helps show where Kitty Yale may publish in the future.

Co-authors

The 25 scholars most cited alongside Kitty Yale, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kitty Yale Line = papers co-authored together Kitty Yale links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks The Lancet ·Paul E. Sax, Edwin DeJesus, Anthony Mills, Andrew Zolopa, Calvin Cohen, David A. Wohl, Joel E. Gallant, Hui C. Liu, Lijie Zhong, Kitty Yale, Kirsten White, Brian P. Kearney, Javier Szwarcberg, Erin Quirk, Andrew Cheng	2012	335
2	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial The Lancet ·Edwin DeJesus, Jürgen K. Rockstroh, Keith Henry, Jean‐Michel Molina, Joseph Gathe, S. Ramanathan, Xuelian Wei, Kitty Yale, Javier Szwarcberg, Kirsten White, Andrew Cheng, Brian P. Kearney	2012	256
3	Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial Nature Medicine ·Stephen A. Harrison, Peter Ruane, B. Freilich, Guy Neff, Rashmee Patil, Cynthia Behling, Chen Hu, Erica Fong, Brittany de Temple, Erik J. Tillman, Tim Rolph, Andrew Cheng, Kitty Yale Hit paper breakdown →	2021	255
4	Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults JAIDS Journal of Acquired Immune Deficiency Syndromes ·Peter Ruane, Edwin DeJesus, Daniel Berger, Martin Markowitz, U. Fritz Bredeek, Christian Callebaut, Lijie Zhong, Srini Ramanathan, Martin S. Rhee, Marshall W. Fordyce, Kitty Yale	2013	247
5	Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial The Lancet. Gastroenterology & hepatology ·Stephen A. Harrison, Juan P. Frías, Guy Neff, Gary A. Abrams, K. Lucas, William Sánchez, Sudhanshu Gogia, Muhammed Y Sheikh, Cynthia Behling, Pierre Bédossa, Lan Shao, Doreen Chan, Erica Fong, Brittany de Temple, Reshma Shringarpure, Erik J. Tillman, Tim Rolph, Andrew Cheng, Kitty Yale Hit paper breakdown →	2023	146
6	Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy: Impact on Bone Mineral Density in HIV-Infected Children PEDIATRICS ·Rachel I. Gafni, Rohan Hazra, James C. Reynolds, Frank Maldarelli, Antonella N. Tullio, Ellen S. DeCarlo, Carol Worrell, John F. Flaherty, Kitty Yale, Brian P. Kearney, Steven L. Zeichner	2006	133
7	Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection AIDS ·Calvin Cohen, Richard Elion, Peter Ruane, David Shamblaw, Edwin DeJesus, Bruce Rashbaum, Steven L. Chuck, Kitty Yale, Hui C. Liu, David R. Warren, S. Ramanathan, Brian P. Kearney	2011	93
8	A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis JHEP Reports ·Stephen A. Harrison, Peter Ruane, B. Freilich, Guy Neff, Rashmee Patil, Cynthia Behling, Chen Hu, Reshma Shringarpure, Brittany de Temple, Erica Fong, Erik J. Tillman, Tim Rolph, Andrew Cheng, Kitty Yale	2022	72
9	Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy for Pediatric HIV Infection PEDIATRICS ·Rohan Hazra, Rachel I. Gafni, Frank Maldarelli, Frank M. Balis, Antonella N. Tullio, Ellen S. DeCarlo, Carol Worrell, Seth M. Steinberg, John F. Flaherty, Kitty Yale, Brian P. Kearney, Steven L. Zeichner	2005	72
10	Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens HIV Clinical Trials ·Anthony Mills, Calvin Cohen, Edwin DeJesus, Cynthia Brinson, Scott Williams, Kitty Yale, Srini Ramanathan, Maggie Haitian Wang, Kirsten White, Susan K. Chuck, Andrew Cheng	2013	61
11	Pharmacokinetics and Dosing Recommendations of Tenofovir Disoproxil Fumarate in Hepatic or Renal Impairment Clinical Pharmacokinetics ·Brian P. Kearney, Kitty Yale, Jaymin Shah, Lijie Zhong, John F. Flaherty	2006	58
12	Single-Dose and Steady-State Pharmacokinetics of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Children Antimicrobial Agents and Chemotherapy ·Rohan Hazra, Frank M. Balis, Antonella N. Tullio, Ellen S. DeCarlo, Carol Worrell, Seth M. Steinberg, John F. Flaherty, Kitty Yale, Marianne Poblenz, Brian P. Kearney, Lijie Zhong, Dion F. Coakley, Stéphane Blanche, Jean Bresson, Judith A. Zuckerman, Steven L. Zeichner	2003	44
13	Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study Clinical Gastroenterology and Hepatology ·Stephen A. Harrison, Juan P. Frías, Kathryn Jean Lucas, Gary Reiss, Guy Neff, Sureka Bollepalli, Yan Su, Doreen Chan, Erik J. Tillman, A. W. Moulton, Brittany de Temple, Arian Zari, Reshma Shringarpure, Tim Rolph, Andrew Cheng, Kitty Yale	2024	37
14	The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers Antiviral Therapy ·Paul Randell, Akil Jackson, Lijie Zhong, Kitty Yale, Graeme Moyle	2010	36
15	Efruxifermin in Compensated Liver Cirrhosis Caused by MASH New England Journal of Medicine ·Mazen Noureddin, Mary E. Rinella, Naga Chalasani, Guy Neff, K. Lucas, Manuel Rodríguez, Madhavi Rudraraju, Rashmee Patil, Cynthia Behling, Mark Burch, Doreen Chan, Erik J. Tillman, Arian Zari, Brittany de Temple, Reshma Shringarpure, Meena Jain, Tim Rolph, Andrew Cheng, Kitty Yale Hit paper breakdown →	2025	19
16	Effect of Tenofovir Disoproxil Fumarate on the Pharmacokinetics and Pharmacodynamics of Total, R‐, and S‐Methadone Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Patrick F. Smith, Brian P. Kearney, Sandra Liaw, Denise Cloen, Julie Bullock, Curtis E. Haas, Kitty Yale, Brent M. Booker, Charles S. Berenson, Dion F. Coakley, John F. Flaherty	2004	16
17	Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH Journal of Hepatology ·Naim Alkhouri, Cayden Beyer, Elizabeth Shumbayawonda, Anneli Andersson, Kitty Yale, Tim Rolph, Raymond T. Chung, Raj Vuppalanchi, Kenneth Cusi, Rohit Loomba, Michele Pansini, Andrea Dennis	2024	14
18	Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial The Lancet ·Mazen Noureddin, Juan P. Frías, Guy Neff, K. Lucas, Cynthia Behling, Pierre Bédossa, Julie Dubourg, Doreen Chan, Mark Burch, Erica Fong, Brittany de Temple, Mataran Valdes minerva, Kim E. Barrett, Reshma Shringarpure, Erik J. Tillman, Tim Rolph, Andrew Cheng, Kitty Yale	2025	5
19	897-P: Insulin-Sensitizing Effects of Efruxifermin Improve Glycemic Control in Patients with MASH and Type 2 Diabetes Diabetes ·Kathryn Jean Lucas, S. Harrison, Doreen Chan, Erik J. Tillman, A. W. Moulton, Brittany de Temple, Arian Zari, RESHMA SHRINGARPURE, Tim Rolph, Andrew Cheng, Kitty Yale	2024	1
20	GS-012 Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, doubleblind, placebo-controlled, phase 2b trial (SYMMETRY) Journal of Hepatology ·Mazen Noureddin, Mary E. Rinella, Naga Chalasani, Guy Neff, Kathryn Jean Lucas, Manuel Rodríguez, Madhavi Rudraraju, Rashmee Patil, Cynthia Behling, Mark Burch, Doreen Chan, Erik R. Tillman, Arian Zari, Brittany de Temple, Reshma Shringarpure, Meena Jain, Tim Rolph, Andrew Cheng, Kitty Yale	2025	0

About Kitty Yale

Kitty Yale is a scholar working on Virology, Infectious Diseases, Hepatology, Emergency Medicine and Epidemiology, having authored 21 papers that have together received 1.9k indexed citations. Recurring topics across this work include HIV Research and Treatment (11 papers), HIV/AIDS drug development and treatment (11 papers), Liver Disease Diagnosis and Treatment (9 papers), HIV/AIDS Research and Interventions (7 papers), Fibroblast Growth Factor Research (5 papers), Kruppel-like factors research (3 papers), Diet, Metabolism, and Disease (3 papers) and HIV-related health complications and treatments (3 papers). The work is most often cited by research in Virology (837 citations), Infectious Diseases (1.2k citations), Emergency Medicine (389 citations), Hepatology (230 citations) and Epidemiology (646 citations). Kitty Yale has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Andrew Cheng, Brian P. Kearney, Edwin DeJesus, Lijie Zhong, Peter Ruane, Kirsten White, Javier Szwarcberg, Tim Rolph, Erik J. Tillman and Brittany de Temple. Their work appears in journals such as Journal of Hepatology, The Lancet, PEDIATRICS, JAIDS Journal of Acquired Immune Deficiency Syndromes and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact